# US 9,518,093 B2 · Topical formulation of arginine-rich cyclic antimicrobial peptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,518,093 B2
- Document ID: US9518093B2
- Status: Granted
- Kind: B2
- Application number: 14/936,474
- Filed: 2015-11-09
- Published: 2016-06-16
- Granted: 2016-12-13
- Earliest claimed: 2006-02-24
- Assignees: Novabiotics Limited
- Applicants: Novabiotics Limited
- Inventors: Deborah O'Neil
- Web page: https://patentgrep.com/patent/US9518093B2

## CPC

- C07K 7/64: Cyclic peptides containing only normal peptide links
- C07K 14/4723: {Cationic antimicrobial peptides, e.g. defensins}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to cyclic cationic peptides and their use in the treatment of microbial infections.

## Claims

### Claim 1

A topical pharmaceutical composition comprising a cyclic peptide and a pharmaceutically acceptable carrier, excipient or diluent; wherein the cyclic peptide comprises from 5 to 13 contiguous arginine residues.

### Claim 2 (depends on 1)

The topical pharmaceutical composition of claim 1, wherein the cyclic peptide comprises 7 contiguous arginine residues.

### Claim 3 (depends on 2)

The cyclic peptide of claim 2, wherein the arginine residues are D-amino acids.

### Claim 4 (depends on 2)

The cyclic peptide of claim 2, wherein the arginine residues are L-amino acids.

### Claim 5

A composition consisting essentially of a cyclic peptide and a pharmaceutically acceptable carrier, excipient or diluent; wherein the cyclic peptide comprises from 5 to 13 contiguous arginine residues.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the cyclic peptide comprises 7 contiguous arginine residues.

### Claim 7 (depends on 6)

The cyclic peptide of claim 6, wherein the arginine residues are D-amino acids.

### Claim 8 (depends on 6)

The cyclic peptide of claim 6, wherein the arginine residues are L-amino acids.